Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Nascent Pharma Holdings's Days Sales Outstanding or its related term are showing as below:
NASC's Days Sales Outstanding is not ranked *
in the Drug Manufacturers industry.
Industry Median: 71.92 * Ranked among companies with meaningful Days Sales Outstanding only.
Nascent Pharma Holdings's Days Sales Outstanding
increased
from Sep. 2023 (1,451.72) to Sep. 2024 (14,676.04).
Nascent Pharma Holdings (OTCPK:NASC) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Nascent Pharma Holdings Days Sales Outstanding Related Terms
Nascent Pharma Holdings Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Nascent Pharma Holdings's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nascent Pharma Holdings Days Sales Outstanding Chart
NASC vs ALID, CPMD, PLSH: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Nascent Pharma Holdings's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nascent Pharma Holdings Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nascent Pharma Holdings's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Nascent Pharma Holdings's Days Sales Outstanding falls into.
Nascent Pharma Holdings Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 14,676.04 mean?
Nascent Pharma Holdings (NASC) has a Days Sales Outstanding of 14,676.04 as of Sep. 2024. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Nascent Pharma Holdings and its competitors.
Is Nascent Pharma Holdings' Days Sales Outstanding too high?
Nascent Pharma Holdings' current Days Sales Outstanding is 14,676.04. The Drug Manufacturers industry median Days Sales Outstanding is 71.92. Nascent Pharma Holdings' value of 14,676.04 is 20306.1% above this industry median. Overall, Nascent Pharma Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Nascent Pharma Holdings' Days Sales Outstanding compare to ALID and CPMD?
Nascent Pharma Holdings' Days Sales Outstanding of 14,676.04 can be compared against companies in the Drug Manufacturers industry. The industry median Days Sales Outstanding is 71.92. Nascent Pharma Holdings' value of 14,676.04 is 20306.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.92, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nascent Pharma Holdings's current Days Sales Outstanding of 14,676.04 is 20306.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Nascent Pharma Holdings and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nascent Pharma Holdings's current Days Sales Outstanding is 14,676.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nascent Pharma Holdings stock overvalued right now?
Nascent Pharma Holdings (NASC) has a current Days Sales Outstanding of 14,676.04. The current Days Sales Outstanding is 14,676.04 and 20306.1% above the Drug Manufacturers industry median of 71.92. Nascent Pharma Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Nascent Pharma Holdings (NASC), the current Days Sales Outstanding is 14,676.04 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nascent Pharma Holdings Inc has acquired a Subsidiary engaged in enforcing and commercializing the patents held by Nascent. The acquired patents cover liquid formulations of cannabis. The patents relate to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance for incorporation into a medicament and for use in pharmaceutical formulations, in particular comprising cannabinoids obtained from cannabis. Patented uses include using the liquid formulations to alleviate numerous debilitating conditions, including cancer, irritable bowel syndrome, chronic pain, post-traumatic stress disorder, anxiety, sleep disorders, and opioid dependencies.
12GF Score
Get the complete analysis for NASC
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NASC has been successfully added to your 
